Craig-Hallum raised the firm’s price target on Grace Therapeutics (GRCE) to $11 from $8 and keeps a Buy rating on the shares following the company’s Phase 3 STRIVE-ON data for GTX-104, which showed a numerical advantage on the primary and positive trends on many secondaries. The firm cites now 90% probability of success in the model as the company is entering the regulatory phase.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRCE: